07:00 , Apr 15, 2013 |  BC Week In Review  |  Clinical News

Therafectin amiprilose Hcl data

BLSI announced that Phase III findings with Therafectin failed to demonstrate a statistically significant difference in the primary end point. The percent of patients achieving a return to baseline or better in the number of...
07:00 , Jul 30, 2009 |  BC Innovations  |  Targets & Mechanisms

The inosine conundrum

Inosine has been known to promote recovery in rat ischemic stroke models, in which broad swaths of the brain are affected, but it remained unclear whether the compound might restore functions mediated by specific brain...
07:00 , May 11, 2009 |  BC Week In Review  |  Company News

Alseres, BioAxone deal

Alseres (formerly Boston Life Sciences Inc. ) is no longer required to pay milestones to BioAxone under a 2006 deal that granted Alseres exclusive, worldwide rights to BioAxone's Cethrin . In return, Alseres has an...
07:00 , Oct 9, 2008 |  BC Innovations  |  Targets & Mechanisms

In the mood for regeneration

Researchers at the University of Texas Southwestern Medical Center have found that lithium, the marketed mood stabilizer, might have utility in spinal cord injury, an indication for which there are no approved drugs. 1 In...
07:00 , May 19, 2008 |  BC Week In Review  |  Clinical News

Cethrin: Phase I/IIa data

Twelve-month data from an open-label, North American Phase I/lla trial showed that 5 of 13 (38%) patients with cervical injury had a 2-grade or better improvement in the American Spinal Injury Association (ASIA) Impairment Scale...
07:00 , May 12, 2008 |  BC Week In Review  |  Company News

Alseres, BioAxone deal

Alseres (formerly Boston Life Sciences Inc. ) received an option to pay a fee in return for reducing the amount of potential milestones and royalties due to BioAxone under a 2007 deal to develop BioAxone’s...
01:10 , Apr 17, 2008 |  BC Extra  |  Financial News

Paratek raises $18 million

Infectious disease company Paratek (Boston, Mass.) raised $18 million in the second and final tranche of a series H round, bringing the total raised in the round to $40 million. Aisling led the financing, as...
07:00 , Mar 24, 2008 |  BioCentury  |  Finance

Nomura's investments

Nomura's investments Nomura's investments Nomura Phase4 Ventures has invested in at least 25 biotechs since 1999. Usually Nomura's contribution for an initial investment will be some $15-$25 million of the round, although in subsequent rounds...
01:48 , Oct 26, 2007 |  BC Extra  |  Financial News

Paratek raises $22 million

Infectious disease company Paratek (Boston, Mass.) raised $22 million in the first tranche of a series H round led by Aisling. New investors D.E. Shaw Group and Boston Life Science joined existing investors Nomura Phase4;...
00:19 , Sep 27, 2007 |  BC Extra  |  Financial News

GlobeImmune raises $41.2 million

GlobeImmune (Louisville, Colo.) raised $41.2 million in a series C round led by Wexford Capital. Other new investors Celgene (CELG); Mellon Family Investment Company; Richard King Mellon Foundation; Eminent Venture Capital Corp.; Boston Life Science...